Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Narula SanjeevChief Financial & Bus. OfficerShares withheld for tax or exercise price · Oct 6, 2026
Breedlove Robert CharlesPrincipal Accounting OfficerShares withheld for tax or exercise price · Sep 3, 2026
Parikh AsitReporting ownerGift · May 22, 2026
Schroeder Theodore RReporting ownerGrant or award · May 19, 2026
Karbe FrankReporting ownerGrant or award · May 19, 2026
Cola Michael FReporting ownerGrant or award · May 19, 2026
Fields HeidiReporting ownerGrant or award · May 19, 2026
Stenhouse MarkReporting ownerGrant or award · May 19, 2026
Topper James NReporting ownerGrant or award · May 19, 2026
Basta Steven LPresident and CEOShares withheld for tax or exercise price · Feb 10, 2026
About Phathom Pharmaceuticals, Inc. (PHAT): stock profile, AI score and financials
Phathom Pharmaceuticals, Inc. (PHAT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAT at 41.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,060 of 2,925 stocks — the bottom half of the AI-ranked universe. PHAT scores in the top quartile across revenue growth (99.4). Areas of concern include balance sheet strength (6.5) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Phathom Pharmaceuticals, Inc. reports quarterly revenue of $74.3M, net income of $-17.6M, an operating margin of -5.3%. Top institutional holders of PHAT by reported 13-F value include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, BlackRock, based on the most recent SEC filings. PHAT trades on the Nasdaq exchange and files with the SEC under CIK 1783183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phathom Pharmaceuticals, Inc. directly from SEC EDGAR.